Gene, Cell, & RNA Therapy Landscape: Q2 2021

David M. Barrett, J.D., M.S. - July 23, 2021

Highlights in the second quarter of 2021 include the approval of a new gene therapy in Japan, the expansion of gene therapy approvals to three new countries, and more!

The second of a new, quarterly publication from ASGCT and Informa Pharma Intelligence, the Gene, Cell, & RNA Therapy Landscape report, is now available! It is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Highlights from the second issue include:

  • One new gene therapy approval in Japan, and approval in additional countries/regions of three previously-approved gene therapies
  • Oncology remaining the most active therapeutic area of research
  • A marked increase in financing for start-ups
  • Overall dealmaking volume increasing from a year ago

Read the Full Report

Click any of the samples below to view the full report:

David M. Barrett, JD, MS is the Chief Executive Officer of the American Society of Gene & Cell Therapy.